Skip to main content
SION
NASDAQ Life Sciences

Sionna Therapeutics Reports Q1 2026 Results, Confirms Strong Cash Position and Upcoming Clinical Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$45.95
Mkt Cap
$2.068B
52W Low
$11.77
52W High
$48.445
52W Position info
290% above low
Off High info
5.2% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

SION has more than doubled off its 52-week low of $11.77 on elevated volume (1.9× avg).

Summary

Sionna Therapeutics announced its Q1 2026 financial results, reporting an increased net loss but confirming a strong cash position of $289.9 million, expected to fund operations into 2028, alongside progress in its clinical trials with data expected this summer.


Key Events · Earnings and Guidance · SION

  • Q1 2026 Financial Results

    The company reported a net loss of $26.8 million for the first quarter of 2026, an increase from $16.5 million in Q1 2025, primarily due to higher R&D and G&A expenses supporting pipeline advancement and growth.

  • Strong Cash Position and Runway

    Sionna Therapeutics ended Q1 2026 with $289.9 million in cash, cash equivalents, and marketable securities, maintaining its projection to fund operations into 2028.

  • Clinical Trial Progress

    Enrollment has been completed in the PreciSION CF Phase 2a trial for NBD1 stabilizer SION-719, and the Phase 1 dual combination trial for SION-451 is ongoing.

  • Upcoming Topline Data

    Topline data from both the SION-719 Phase 2a trial and the SION-451 Phase 1 dual combination trial are anticipated in the summer of 2026.


Analysis · SION · Life Sciences

Sionna Therapeutics reported an increased net loss for Q1 2026, driven by higher research and development and general and administrative expenses as the company advances its clinical pipeline. Despite the increased burn, the company maintains a robust cash position of $289.9 million, which is projected to fund operations into 2028. This extended cash runway is a critical de-risking factor for a clinical-stage biotech. Additionally, the company confirmed significant pipeline progress with the completion of enrollment in its Phase 2a trial for SION-719 and ongoing Phase 1 trial for SION-451, with topline data for both programs anticipated in the summer of 2026. These upcoming data readouts are key milestones that could significantly impact the company's valuation.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SION was trading at $45.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $11.77 to $48.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SION - Latest Insights

SION
Nov 10, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $3.42 info
Change: -$0.105 (-3%) info
Market Cap: $154.479M info
SION
Sep 17, 2026, 5:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $7.41
Real-time Price: $3.42 info
Change: -$4.00 (-54%) info
Market Cap: $154.479M info
SION
Sep 14, 2026, 4:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $7.93
Real-time Price: $3.42 info
Change: -$4.51 (-57%) info
Market Cap: $154.479M info
SION
Sep 14, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.20
Real-time Price: $3.42 info
Change: -$4.78 (-58%) info
Market Cap: $154.479M info
SION
Aug 10, 2026, 9:07 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $5.34
Real-time Price: $3.42 info
Change: -$1.92 (-36%) info
Market Cap: $154.479M info